Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Global Peripheral Blood Mononuclear Cells Research Report 2023: R&D Revolution - PBMCs Paving the Way for Medical Breakthroughs

Research and Markets Logo

News provided by

Research and Markets

Oct 04, 2023, 20:15 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, Oct. 4, 2023 /PRNewswire/ -- The "Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Application, By Techniques, By Source, By Region, Competition, Forecast and Opportunities" report has been added to  ResearchAndMarkets.com's offering.


Global peripheral blood mononuclear cells market was valued at USD 235.68 million in 2022 and is anticipated to grow at a CAGR of 10.39% during the period 2023-2028 owing to the rising rate in the number of cell therapies, high demand of research, and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products.

For instance, in June 2023, a study published in the National Library of Medicine assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.

PBMCs are widely used in various research applications, including immunology, cell therapy, vaccine development, and drug discovery. They provide valuable insights into immune responses, allow researchers to study various immune cell populations, and serve as a source of cells for cell-based therapies. PBMCs can be isolated from peripheral blood using techniques such as density gradient centrifugation or specialized cell separation methods.

Additionally, the rise in number of cell therapies, expansion in research & development schemes, increasing focus of key players on R&D in peripheral blood mononuclear cells, increasing focus on regenerative medicine, as well as an increase in demand for cell operations among the population, increasing investigation of various aspects of immunology, infectious diseases, autoimmune disorders, transplantation, and vaccine development are projected to provide market players with lucrative prospects in the future.

Advancements in Toxicology Research

The growth of the peripheral blood mononuclear cells (PBMC) industry is fueled by increasing customer awareness and a rising preference for antibody development. PBMCs play a vital role in biology, pathology, clinical research, and the study of diseases, immunology, and vaccine development. Notably, clinical trials involving PBMCs have surpassed 972 studies, underscoring their significance.

PBMCs provide valuable insights into the effects of potential medication on individuals, particularly their immune systems. Toxicity affecting PBMCs can lead to severe, even fatal, side effects, including immune system suppression and poisoning. Toxicology research is dedicated to evaluating the adverse effects of chemicals, drugs, and environmental factors on living organisms.

In immunotoxicity studies, PBMCs are pivotal for assessing the impact of substances on the immune system. Researchers expose PBMCs to various compounds, analyzing immune responses and identifying immunotoxic effects, including changes in immune cell populations, cytokine production, and immune function. As demand for PBMCs in immunotoxicity research grows, the global peripheral blood mononuclear cells market continues to expand.

Rising Significance of PBMCs in Cell Therapy

Peripheral blood mononuclear cells (PBMCs) are gaining prominence in cell and gene therapy, offering an alternative to traditional regenerative medicines with fewer side effects. In regions like North America and Europe, PBMCs are integral to cell therapies for human well-being.

Awareness is growing about the utility of PBMCs in various treatments, including acute myocardial infarction, chronic heart failure, spinal cord injury, stroke, and wound healing. Successful pre-clinical studies using apoptotic PBMCs' secretome indicate significant market growth potential.

For example, the Centers for Disease Control and Prevention reports approximately 37,300 new cases of HPV+ tumors annually in the U.S., making up 3% of women's malignancies and 2% of men's cancers. With increasing HPV prevalence, companies are focusing on therapy and drug development for the U.S. market, with PBMCs serving as a valuable source of immune cells for cell therapy.

PBMCs encompass various immune cells, including T cells, B cells, and natural killer (NK) cells, all critical for immune responses and disease targeting. These cells provide a versatile resource for different cell therapy approaches.

Adoptive Cell Transfer (ACT), a cell therapy involving immune cell transfer to target diseases like cancer, often starts with PBMCs for isolating and expanding specific T cell subsets. These cells are essential for ACT therapies, supporting market growth.

Increased Investment in R&D for Human Well-Being

The market's growth is driven by rapid advancements in research and development (R&D), leading to novel cell/gene therapies, medications, and products for treating fatal diseases.

PBMCs offer a practical means of obtaining immune proteins from routinely collected blood samples, addressing the analytical challenges posed by highly abundant proteins in native human plasma. Governments worldwide are providing funding for ongoing PBMC research to boost healthcare sector growth.

Moreover, growing awareness of PBMCs' potential in disease research has spurred increased R&D activities, boosting the PBMCs market. PBMCs play a crucial role in early-stage research, assessing the efficacy and safety of potential drug candidates.

As a human-relevant model for studying immune responses and the effects of new compounds on immune cells, PBMCs are increasingly valued in drug discovery. This awareness has fueled demand, driving market growth.

The therapeutic potential of cell-based therapies has been rapidly recognized, with PBMCs playing a pivotal role in their development and manufacturing. Collaborative efforts between academic institutions, research organizations, and the biopharmaceutical industry have contributed to knowledge exchange, joint research projects, and funding initiatives centered on PBMC application in various research areas. This growing awareness and collaborative R&D efforts positively impact the global peripheral blood mononuclear cells market's growth.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global peripheral blood mononuclear cells market.

  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Corning Inc
  • Bio-Rad Laboratories Inc
  • ABCAM
  • Biolegend Inc
  • ZEN-Bio Inc
  • DAPCEL, Inc.
  • Creative Bioarray
  • iXCells Biotechnologies USA, LLC
  • Miltenyi Biotec B.V. & CO. KG
  • STEMCELL Technologies Inc.
  • Precision Medicine Group, LLC.
  • StemExpress, LLC
  • RayBiotech Life, Inc.
  • REPROCELL Inc.
  • Cytologics LLC
  • BioIVT LLC
  • Biopredic International
  • Cell Applications, Inc.

Report Scope:

Voice of Customer

  • By Type of Product
  • By Type of Technique
  • Type of Application for Which PBMCs Are Used
  • Factors Driving Market Growth

Clinical Trial Analysis

  • Ongoing Clinical Trials
  • Completed Clinical Trials
  • Terminated Clinical Trials
  • Breakdown of Pipeline, By Development Phase
  • Breakdown of Pipeline, By Status
  • Breakdown of Pipeline, By Study Type
  • Breakdown of Pipeline, By Region
  • Clinical Trials Heat Map

Peripheral Blood Mononuclear Cells Market, By Product:

  • Cryopreserved or Frozen PBMC
  • Cultured or Fresh PBMC
  • Others

Peripheral Blood Mononuclear Cells Market, By Application:

  • Immunology
  • Hematology
  • Infectious Disease
  • Others

Peripheral Blood Mononuclear Cells Market, By Techniques:

  • Density Gradient Centrifugation
  • Leukapheresis
  • Others

Peripheral Blood Mononuclear Cells Market, By Source:

  • Human
  • Animal

Peripheral Blood Mononuclear Cells Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa

For more information about this report visit https://www.researchandmarkets.com/r/luh8hf

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.